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Abstract
Background
Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology
affecting mainly children less than 5 years of age. Risk factors for cardiac involvement and
resistance to treatment are insufficiently studied in non-Japanese children.
Objective
This study aimed to investigate the epidemiology, clinical features and risk factors for resis-
tance to treatment and coronary artery lesions (CAL) in KD in Spain.
Methods
Retrospective study (May 2011-June 2016) of all patients less than 16 years of age diag-
nosed with KD included in KAWA-RACE network (84 Spanish hospitals).
Results
A total of 625 cases were analyzed, 63% were males, 79% under 5 year-olds and 16.8%
younger than 12 months. On echocardiographic examination CAL were the most frequent
findings (23%) being ectasia the most common (12%). Coronary aneurysms were
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diagnosed in 9.6%, reaching 20% in infants under 12 months (p<0.001). A total of 97% of
the patients received intravenous immunoglobulin (IVIG) with a median number of days
from fever onset to IVIG administration of 7.2. A second dose was given to 15.7% and ste-
roids to 14.5% patients. Only 1.4% patients received infliximab. No deaths were reported. A
multivariate analysis identified anemia, hypoalbuminemia, hyponatremia, higher creatinine
and procalcitonin as independent risk factors for treatment failure and length under 103 cm,
hemoglobin < 10.2 mg/dL, platelets > 900,000 cells/mm3, maximum temperature < 39.5˚C,
total duration of fever > 10 days and fever before treatment� 8 days as independent risk
factors for developing coronary aneurysms.
Conclusions
In our population, children under 12 months develop coronary aneurysms more frequently
and children with KD with anemia and leukocytosis have high risk of cardiac involvement.
Adding steroids early should be considered in those patients, especially if the treatment is
not started before 8 days of fever. A score applicable to non-Japanese children able to pre-
dict the risk of aneurysm development and IVIG resistance is necessary.
Introduction
Kawasaki disease (KD) is an acute self-limited systemic vasculitis of unknown etiology present-
ing predominantly in children less than 5 years of age. Diagnosis is based on clinical criteria
that include fever, exanthema, conjunctivitis, changes in the extremities, erythema of oral
mucosa and lips and cervical lymphadenopathy. The prognosis depends mainly on the extent
of cardiac involvement that can be minimized if treatment with intravenous immunoglobulin
(IVIG) is administered before the 10th day of disease[1,2].
The etiology of KD is still unknown, although clinical, laboratory and epidemiological fea-
tures suggest an infectious origin or trigger. However, many studies have failed to identify a
unique etiological infectious agent and studies on other biomarkers have tried to recognize the
disease early[3,4]. On the other hand, activation of the immune system is characteristic of KD
and genomewide association studies have identified a number of plausible loci involved in KD
[5–8]. To date, KD diagnosis is still mainly based on clinical criteria although a recent study
has described a 13-transcript blood gene expression signature that distinguished KD from
other febrile conditions[9].
KD has a universal distribution but is more prevalent in Asian countries, especially in Japan,
with an increasing annual incidence of 308 per 100,000 children<5 years in 2014[10]. In
Europe incidences range between 4.9 and 15.2 per 100,000 children<5 years of age[11,12]. In
Spain, the first population-based study on the epidemiology of KD was published by the KD
Catalonian Working Group reporting a mean annual incidence in Catalonia of 3.5/100,000 chil-
dren<14 years old and 8/100,000 children<5 years (2004–2013)[13]. More recently an inci-
dence of 11.7/100,000 children<5 years has been reported (2005–2015) for the whole of Spain,
but this study was a retrospective ecological study and may be overestimating the real incidence
[14,15]. Surveillance KD studies are important to monitor trends and outcomes of the disease.
In 2015 a KD study group named KAWA-RACE was set up aiming to investigate the epide-
miology, clinical features, risk factors for coronary artery lesions (CAL), specially coronary
aneurysms, management and outcome of KD in Spain.
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Materials and methods
Network setup: During 2015 a call for pediatricians who work with KD patients was sent out
through the national societies of infectious diseases, rheumatology and cardiology to set up a
KD study group that was named KAWA-RACE. A total of 187 pediatricians from 84 Spanish
hospitals joined the network. The ethics committee at Instituto de Investigacio´n Hospital 12
de Octubre approved this study (CEIC 15/316). All patient data were fully anonymized before
we accessed them.
Data source and collection: We identified all children who were discharged from these hos-
pitals with an International Classification of Diseases (ICD) coding for KD (ICD9 446.1). Ret-
rospective medical data retrieval from 5 years (May 2011–June 2016) was collected and
reviewed. A research electronic database capture [16] was created and sent to the participant
clinicians together with the study protocol. The patient’s demographic, clinical, laboratory and
echocardiographic data were recorded. Egami[17], Sano[18] and Kobayashi[19] scores were
calculated.
Subjects and Case Definitions: Individual patient data were reviewed to confirm the diag-
nosis of KD according to the American Academy of Pediatrics and the American Heart Asso-
ciation (AHA) in 2004[20], including coronary aneurysms criteria. Diagnosis of incomplete
KD was made in cases with fewer classical diagnostic criteria and with several compatible clini-
cal, laboratory, or echocardiographic findings, excluding those of other febrile illnesses accord-
ing to AHA. All patients less than 16 years of age diagnosed with KD diagnosis were included
in the study. Exclusion criteria were: Patients older than 16 years at the time of diagnosis,
those patients found to be duplicated in the database and patients with a final alternative
diagnosis.
Resistance to treatment was defined as persistence of fever 36 hours after the end of IVIG
infusion. Minimum follow up was considered 6 months.
Statistical Analysis: Baseline characteristics were described through summary tables report-
ing frequencies and total records in case of categorical variables and mean (standard deviation)
or median (interquartile range (IQR)) when continuous. Chi-squared and Fisher-test (low cell
sizes <20) were applied to assess differences among groups for categorical variables. For con-
tinuous variables Student T-test and U-Mann-Whitney were applied in parametric and non-
parametric distributions respectively. Normality was tested by means of Shapiro-Wilk test.
Optimal cutpoint for continuous variables were assessed by means of the maximum AUC val-
ues predicting aneurism including 100 bootstrapped samples implemented in cutpoint pack-
age[21]. In order to estimate the effect of the different sociodemographic and clinical
characteristics with the primary outcomes odds ratios (ORs) were calculated by means of nor-
mal and multivariable logistic regression adjusting for age at hospitalization. To test possible
non-linear associations with the risk of developing aneurisms, a generalized additive logistic
model was performed, and the probability risk of developing aneurism was plotted either for
univariate or multivariate analysis. Smoothing parameters defining degrees of freedom (df)
were selected according to nested AIC comparisons. Plots were built with ggplot2 and itsadug
R packages. R software was used for all analysis[22].
Results
Epidemiology
Nationwide, 654 cases were collected, 29 cases were excluded for not meeting inclusion crite-
ria. Thus, 625 cases were included for analysis. Sixty-three percent were males giving a gender
ratio of 1.58:1 and age at diagnosis ranged from 49 days to 15.6 years (median: 2.8 years). Over
Kawasaki disease features in Spain (2011-2016) and risk factors for aneurysm development
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all 494 (79%) cases occurred in children under 5 years. Forty-two cases (6.7%) were younger
than 6 months and 103 cases (16.5%) younger than 12 months. The patients were mainly of
European origin (76%) followed by Central and South America (6%) and Asia (5%). A total of
441 were classified as complete (70.5%) and 184 as incomplete (29.5%) KD. Amongst patients
younger than 6 and 12 months the proportion of incomplete cases was significantly higher
than the group older than 6 and 12 months (52% vs 28%, p<0.001) and (25% vs 14%,
p<0.001), respectively. In 13 (2%) cases it was not the first episode of KD. The onset of KD
was more common in winter (28%) and spring (28%), whereas it was relatively less frequent in
autumn (19%). Fig 1 represents age (A) and seasonal distribution (B).
Data on family history for first and second degree relatives was available for 560/625
patients and only 5 (0.9%) patients reported relatives with previous KD; in 2 cases it was the
mother; in 2 cases, a cousin and in 1 case, a sibling.
Clinical characteristics
Clinical data of the patients are shown in Table 1. The most common manifestation was fever
persisting for 5 days or longer (99.5%) followed by lips and oral changes in both complete and
incomplete forms. Only 8% reported that fever was preceded by another symptom. We com-
pared the data between complete and incomplete KD (Table 1) and changes in extremities and
acute lymphadenopathy were the least common classical diagnostic criteria present in incom-
plete cases. Desquamating rash on the groin was significantly less frequent in incomplete KD
(17% vs 12%, p 0.008).
Despite diagnosing and treating for KD, clinicians suspected a different entity in 21% of
cases, mainly scarlet fever followed by viral infections. A positive microbiological finding was
found in 101 (16%) patients, and they were mainly respiratory viruses (35 cases) and pharyn-
geal Streptococcus group A (29 cases).
On laboratory findings, children with incomplete KD had significantly lower hemoglobin
levels (median value 10.6g/L vs 11.0 g/L, p<0.001) and higher white cell count (median value
19,500x109/L vs 15,850x109/L, p<0.001) (Table 2). The overall terminal segment of the natri-
uretic atrial peptide (NT-proBNP) before treatment was (median IQR; 394 (180–1034) pg / ml.
Heart lesions
Electrocardiographic studies during admission revealed alterations in 47/608 (7.7%) patients,
mainly of low voltage in 18 cases, and followed by repolarization alterations in 11 cases.
Fig 1. Age (A) and seasonal (B) distribution of Kawasaki disease patients in Spain, from 2011 through 2016.
https://doi.org/10.1371/journal.pone.0215665.g001
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Echocardiographic examinations were performed during the acute phase of KD in 99% of
the cases, among which 32% were found to have an abnormal echocardiogram. CAL were the
most frequent findings in 144 patients (23% of cases). Of these, ectasia was the most common
lesion, diagnosed in 75/621 patients (12% of cases). Coronary aneurysms were diagnosed over-
all in 60/621 patients (9.6%) and in 21/103 (20%) infants under 12 months (p<0.001). Twenty-
eight aneurysms persisted more than 6–8 weeks (4.5% of the total patients). Five cases were
diagnosed with giant aneurysms (0.8%). Other data are shown in Table 3. Only 127/621
patients underwent tests looking for peripheral aneurysms and of these 26 (20%) were diag-
nosed of a peripheral aneurysm, mainly by doppler ultrasound.
Treatment and outcome
Treatment with IVIG was given to 97% of the patients (606 cases). The median number of
days since the first day of fever to IVIG administration was 7.2 (range 0–67) and overall 85%
of the children (83% with incomplete and 86% with complete KD) received IVIG within the
first 10 days from the onset of the disease. Only 9.5% of patients reported side effects, mainly
Table 1. Epidemiological and clinical findings in children with Kawasaki disease. Comparison between complete and incomplete cases.
Variable Complete KD
N = 441 (70.5%)
Incomplete KD
N = 184 (29.4%)
p-value
Gender
Male 281 (64) 113 (61.4) 0.602
Age
<12 months 60 (13.6) 45 (24.4) 0.001
Age at admission (mean), years 2.92 (1.36–4.35) 1.94 (0.86–3.78) 0.001
Classical criteria
Conjunctival injection 407 (93.8) 122 (67.0) <0.001
Lips and oral changes 417 (96.3) 146 (79.8) <0.001
Changes in extremities 347 (81.5) 96 (53.3) <0.001
Polymorphous exanthema 403 (94.4) 124 (68.9) <0.001
Acute lymphadenopathy 317 (74.2) 84 (46.1) <0.001
Other findings
Respiratory
Wheezing 9 (2.0) 7 (3.8) 0.373
Musculoskeletal
Arthritis, arthralgia (pleocytosis of synovial fluid) 62 (14.0) 21 (11.6) 0.603
Gastrointestinal
Diarrhea, vomiting, abdominal pain 154 (34.9) 71 (38.8) 0.826
Hepatitis, jaundice 133 (30.1) 60 (33.0) 0.512
Gallbladder hydrops 15 (3.4) 7 (3.8) 0.079
Pancreatitis 1 (0.2) 1 (0.5) 0.827
Nervous system
Irritability 184 (41.7) 90 (48.9) 0.360
Aseptic meningitis (before IVIG) 8 (1.8) 5 (2.7) 0.097
Sensorineural hearing loss 1 (0.2) 0 (0) 0.626
Genitourinary
Hematuria 21 (4.7) 11 (6) 0.836
Sterile pyuria 108 (24.5) 54 (32.7) 0.614
Other
Desquamating rash in groin 74 (17.2) 22 (12.1) 0.009
https://doi.org/10.1371/journal.pone.0215665.t001
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fever recrudescence during infusion (8 cases; 1.3%) and neck stiffness (6 cases; 1%). The
majority of patients received acetyl salicylic acid (543/625, 87%). Among the patients treated
with IVIG, 15.7% (98 cases) did not respond and received a second dose and 1.6% (10 cases)
required a further dose. Steroids were given to 91 (14.5%) patients, 18 of whom (20%) received
them as initial therapy together with IVIG. A higher, non-significant proportion of patients
that received steroids were< 6 months (23.8% vs 13.8%, p 0.124). Only 9 (1.4%) patients
received other immunosuppressive therapies, infliximab in all of them. Blood transfusions for
anemia were required in 4 (0.6%) patients. Only one case of neurosensory hearing loss was
described. Out of the 30 (5%) patients admitted to the pediatric intensive care unit, a signifi-
cantly higher proportion of them were younger than 6 months (18% vs 4%, p = 0.002). The
main cause of admission was suspicion of sepsis (37%) and myocardial dysfunction (17%).
Permanent sequelae were reported in 27 (4.3%) patients, mainly due to permanent CAL (giant
aneurisms in 2 cases; 7% of patients with sequelae); one patient had myocardial dysfunction,
Table 2. Blood test results in children with Kawasaki disease (KD). Comparison between complete and incomplete cases.
Variable Median [IQR] n/N Complete KD [N = 441 (70.5%)] Incomplete KD [N = 184 (29.4%)] p-value
Hemoglobin g/dl (min) 11.00 [10.2–11.9] (n = 432) 10.6 [9.8–11.6] (n = 180) <0.001
White cell count x109/L (max) 15,815 [12,650–20,477](n = 350) 19,500 [14,950–22,700] (n = 135) <0.001
Platelets x1012/L (min) 327,000 [252,500–402,000] (n = 423) 335,500 [255,250–414,500] (n = 180) 0.883
Platelets x1012/L (max) 574,000 [453,500–731,000] (n = 423) 600,500 [458,000–805,500] (n = 180) 0.254
ESR mm/h 72.0 [48.0–102.7] (n = 350) 75.0 [43.7–104.7] (n = 140) 0.791
CRP mg/l 15.0 [6.9–32.3] (n = 430) 13.2 [7.1–23.3] (n = 180) 0.267
Albumin g/L 3.1 [2.7–3.6] (n = 334) 3.2 [2.6–3.8] (n = 146) 0.913
ALT IU/L 45.5 [20.0–100.2] (n = 400) 35.0 [20.0–86.5] (n = 170) 0.473
NT-proBNP pg/ml 460.5 [200.2–1336.5] (n = 68) 444.0 [228.0–986.5] (n = 18) 0.983
IQR: interquartile range, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, ALT: Alanine transaminase, NT-proBNP: N-terminal pro b-type natriuretic
peptide
https://doi.org/10.1371/journal.pone.0215665.t002
Table 3. Cardiological findings in children with Kawasaki disease.
Finding Total patients = 625
Coronary artery lesions 144 patients (23%)
Ectasia 75 patients (12%)
Coronary aneurysms 60 patients (9.6%)
Number of aneurysms (mean, range) 1.82 (1–6)
Diameter of aneurysms (mean, range) 4.2 (2.1–12) mm
Giant aneurysms (cases) 5 (0.8%)
Number of affected vessels (mean, range) 1.8 (1–4)
Coronary affected Left main coronary artery (23/60; 38%)
Right coronary artery (19/60; 31%)
Left anterior descending artery (13/60; 21%)
Left circumflex coronary artery (6/60; 10%)
Persistence aneurysms (> 6–8 weeks) 28 (4.5%)
Valvular involvement 57 patients (9.2%)
Mild and transient mitral valve insufficiency (6.7%)
Pericardial effusion 48 patients (7.7%)
Transient left ventricular systolic dysfunction 7 patients (1.1%)
https://doi.org/10.1371/journal.pone.0215665.t003
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another complete atrioventricular heart block and a third hemophagocytic lymphohistiocyto-
sis. No deaths were reported.
Risk factors for resistance to treatment
A total of 98 (15.7%) children had IVIG resistance and needed a second dose. A univariate analy-
sis was performed to identify the possible risk factors for resistance to treatment (Table 4). Non-
responder patients had a higher proportion of aneurysms (15% vs 8%), lower hemoglobin, albu-
min and sodium in serum and higher maximum platelet and leucocyte count, higher creatinine,
and procalcitonin in serum. The clinical data were similar between responders and non-respond-
ers except for the presence of rash that was more frequent in those who had resistance to treat-
ment. When a multivariate analysis was performed, anemia, hypoalbuminemia, hyponatremia
and higher creatinine and procalcitonin were independent risk factors for non-response to the ini-
tial IVIG (Table 4). Although fever until treatment> 8 days was associated with non-response, it
did not remain significant in the multivariate analysis and neither did the Kobayasi score.
When risk scores of non-response to the initial IVIG were analyzed, children that needed a
second dose of IVIG had more frequently a Kobayasi score� 5. No differences were found in
the mean Egami and Sano scores between responders and no responders. The sensitivity and
specificity of the scores are detailed in Table 5.
Risk factors for developing coronary aneurysms
A total of 60 children (9.6%) developed coronary aneurysms. A univariate analysis was also
performed to identify risk factors for developing coronary aneurysms (Table 6). Children with
Table 4. Risk factors for resistance to treatment with IVIG. Univariated and multivariated analysis.
Univariate Analysis
OR [95% CIs]
p-value Multivariate Analysis�
OR [95% CIs]
p-value
Age at hospitalization (y)
�1 1.5 [0.85;2.5] 0.151 - -
Hemoglobin (g/dl)
<10.2 2.5 [1.61;3.94] <0.001 2.5 [1.54;4.12] <0.001
Sodium (meq/L)
<136 3.5 [2.54;6.45] <0.001 2.9 [1.7;5.4] <0.001
Creatinine (mg/dl)
�0.4 2.5 [1.5;4.2] <0.001 3.2 [1.8;5.9] <0.001
Albumin (g/L)
<3.3 2.9 [1.7;5.1] <0.001 3.1 [1.8;5.6] <0.001
Procalcitonin (ng/mL)
�5.5 5.5 [2.1;14.0] 0.001 9.4 [3.3;27.9] <0.001
Aneurysm
Yes 1.95 [1.00;3.59] 0.049 2.3 [1.1;4.4] 0.002
Fever duration until treatment (d)
�8 3.0 [1.7;5.4] 0.001 0.7 [0.42;1.2] 0.251
Kobayashi
�5 points 1.9 [1.1;3.38] 0.031 1.5 [0.78;2.9] 0.204
Echocardiogram alterations
Yes 2.2 [1.44;3.48] <0.001 1.9 [1.1;3.0] 0.012
� Adjusted by Age at hospitalization.
https://doi.org/10.1371/journal.pone.0215665.t004
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coronary aneurysms were younger (mean of 23 vs 34 months), weighed less than 14 kg and
had a height under 103 cm more frequently. The group between 6 and 12 months developed
aneurysms in a significantly high proportion of cases, up to 23%. Males developed aneurysms
more frequently. A higher proportion of children that developed aneurisms had duration
of fever for longer than 10 days and oral lesions were less common. Hypotension and shock
were also more frequent in children without coronary aneurysms. Regarding blood analysis,
anemia; higher value of maximum platelets and leucocytes were present in children with
aneurisms.
None of the analyzed scores (Egami, Sano or Kobayashi), nor the type of KD (complete or
incomplete) were associated with higher risk of aneurysms. Children who suffered from a pre-
vious infection or those with a microbiological identification presented the same proportion of
aneurysms. Patients with aneurysms more frequently received steroids and infliximab.
When a multivariated analysis was performed we found that independent risk factors for
developing coronary aneurysms were, length under 103 cm; OR = 4.9 [CI 95%: 1.3–31.7],
hemoglobin < 10.2 mg/dL; OR = 2.2 [CI 95%: 1.2–4.1], platelets > 900,000 cells/mm3;
OR = 3.3 [CI 95%: 1.54;6.99], maximum temperature < 39.5˚C; OR = 2.8 [CI 95%: 1.1–9.70],
duration of fever> 10 days; OR = 4.8 [CI 95%: 2.54–9.11] and fever before treatment� 8 days
OR: 3.9 [CI 95%: 2.1;7.5] (Fig 2).
According to the generalized additive logistic model, age at hospitalization (df = 4), hemo-
globin (df = 5), platelets (df = 6), maximum temperature (df = 5) and leukocytes presented a
Table 5. Scores for the prediction of resistance to treatment with IVIG and its applicability in the Spanish population.
EGAMI KOBAYASHI SANO
�4 days of illness (1 p) Na�133 (2 p) Total bilirrubin�0.9 mg/dl (1 p)
ALT >100 U/L (1 p) �4 days of illness (2 p) AST�200 U/L (1 p)
�300 x109/L platelets (1p) ALT� 100 U/L (1 p) CRP�7 mg/dL (1 p)
CRP�8 mg/dL (1 p) �300 x109/L platelets (1 p)
Age �6 months (2 points) CRP�10 mg/dL (1 p)
Age�12 months (1 p)
�80% neutrophils (2 p)
High risk �3 points �5 points �2 points
Coronary artery lesions
Sensitivity (%) 26 25 24.6
Specificity (%) 70 75 79
PPV (%) 52 49 47
NPV (%) 42 52 58
Coronary aneurysms
Sensitivity (%) 24 22 14
Specificity (%) 70 70 64
PPV (%) 38 32 23.5
PNV (%) 54 59 49
Resistance to IVIG
Sensitiviity (%) 34 35.4 25
Specificicity (%) 75 77.4 79
PPV (%) 23 25.6 22.4
NPV (%) 84 84 84.4
ALT, alanine aminotransferase; AST, aspartato aminotransferase; CRP, C reactive protein; IVIG, intravenous immunoglobulin; PPV, predictive positive value; PNV,
predictive negative value.
https://doi.org/10.1371/journal.pone.0215665.t005
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non-linear association with the probability risk of developing aneurism. Interestingly, days of
fever until IVIG treatment (df = 7) presented a concave curve effect in the multivariate and a
bimodal for the univariate. The probability of developing aneurisms was higher in younger age
at hospitalization (0–4 years), reaching a plateau effect from 8 years of age. A similar associa-
tion was found for hemoglobin and maximum temperature, when hemoglobin and tempera-
ture increase, the probability of aneurisms decreases exponentially until they reach values of
10g/dl and 40˚C respectively of plateau effect. Higher levels of platelets and leukocytes increase
the risk of developing aneurisms. These effects were more pronounced after 1,000,000 plate-
lets/mm3 and 30,000 leukocytes/mm3 (Fig 3).
Discussion
This is the first national multicenter epidemiological and clinical study on KD in Spain. From
a total of 625 children with KD, coronary aneurysms were detected in 60 cases (9.6%), and we
identified as primary risk factors associated with their development, the presence of anemia;
child’s height bellow than 103 cm, maximum platelets greater than 900,000 / mm3, the total
duration of fever greater than 10 days and the duration of fever > 8 days before treatment. In
our series, resistance to IVIG treatment was found in more than 15% of the cases, with the
development of aneurysms being more frequent in those cases. The known predictive scores of
treatment failure are not applicable in our population as it has been described in other non-
Japanese populations[23,24].
Table 6. Risk factors for developing aneurysms. Univariate and multivariate analysis.
Univariate Analysis
OR [95% CIs]
p-value Multivariate Analysis�
OR [95% CIs]
p-value
Age at hospitalization (y)
�1 3.4 [1.97; 6.64] 0.002 - -
Gender
Male 2.4 [1.2;5.03] <0.001 - -
Weight (kg)
� 14 3.1 [1.5,7.0] 0.001 2.2 [0.85;6.1] 0.111
Length (cm)
� 103 5.3 [1.8,7.0] 0.001 4.9 [1.3;31.7] 0.038
BMI
> 18.3 0.7 [0.2,2.0] 0.112 0.4 [0.1;1.44] 0.230
Hemoglobin (g/dl)
� 10.2 2.4 [1.10;4.42] <0.001 2.2 [1.2;4.1] 0.012
Platelets (cell/mm3)
> 900,000 4.6 [2.4;8.51] <0.001 3.3 [1.54;6.99] 0.002
Leukocytes (cell/mm3)
> 16,800 2.2 [1.1;8.10] <0.001 1.5 [0.66;3.53] 0.341
Maximum Temperature (˚C)
� 39.5 2.7 [1.15;8.15] <0.001 2.8 [1.1;9.70] 0.006
Total fever duration (d) from the beginning of symptoms
> 10 3.6 [2.0;6.3] <0.001 4.8 [2.6;9.3] <0.001
Fever duration before treatment (d)
�8 3.0 [1.7;5.4] <0.001 3.9 [2.1;7.5] <0.001
� Adjusted by age at hospitalization and gender.
https://doi.org/10.1371/journal.pone.0215665.t006
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The epidemiology of our patients is similar to that described in other countries around us.
Gender and age distribution were similar to most reports, boys were more commonly affected
and most of the cases occurred in children <5 years with incidence peaking in children 1 year
of age[1,13,25]. The male/female reported ratio is approximately 1.5 to 1 and is consistent with
Fig 2. Specific risk factors for developing coronary aneurisms among patients with Kawasaki disease in Spain (2011–2016).
https://doi.org/10.1371/journal.pone.0215665.g002
Fig 3. Probability of coronary aneurisms according to specific risk factors among patients with Kawasaki disease in Spain (2011–2016).
https://doi.org/10.1371/journal.pone.0215665.g003
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our findings[26]. The most commonly affected race was of European origin representing the
main population in our country. The seasonal distribution of incidence rates were maximum
during winter and spring as reported in European and most Asian studies [27,28] and differing
from some Asian studies that report greater incidence during summer[25].
The clinical manifestations of KD in Spain were very similar to those shown in other studies
[13,25,29]. The rate for incomplete forms of KD in our study (29.6%) was within the range of
those reported in the literature but lower than the rate described in a Spanish study performed
in the region of Catalonia (39.8%) possibly indicating increased awareness of KD in this region
[13]. Fever persisting for 5 days or longer was still the most frequent clinical manifestation of
KD, followed by changes of lips and the least frequent symptom was acute non-purulent cervi-
cal lymphadenopathy[30].
Children with KD typically have leukocytosis. Many children have a normocytic normo-
chromic anemia and platelet counts are usually elevated by the end of the first week of illness
with counts exceeding 1 million/mm3 in some cases. Inflammatory markers are elevated in
nearly all patients with KD. Measurements of the erythrocyte sedimentation rate (ESR) are
helpful in assessing the degree of inflammation at diagnosis and before IVIG administration.
The analytical values of our patients were also similar to those previously described[30]. In our
series, the presence of anemia, hypoalbuminemia, hyponatremia and elevation of procalcito-
nin were risk factors for non-response to treatment and anemia was also an independent risk
factor for development of aneurysms. Chen et al, also found anemia as a risk factor for the
development of CAL but did not specify if this also applies to aneurysms alone[25]. Recently,
hepcidin has been described as inducing transient hyposideremia, anemia, and hypothesized
to influence disease outcomes in KD[31]
The percentage of coronary dilation (ectasia) in our series was lower (12%) than in other
series that describe an incidence of up to 30% of children by Z-score criteria (Z>2), even when
treated with high-dose IVIG regimens within the first 10 days of illness[1]. The percentage of
coronary aneurysms (9.6%) and giant aneurysms (0.8%) in our cohort is high when compared
to Asian series (Japan (1.05 and 0.91%)[10], Korea (1.7 and 0.16%)[32] and Shanghai (1.1 and
0.7%)[25] but smaller than those published in USA (13%) [33], The Netherlands (13.5%)[26],
Germany (17%)[28] or United Kingdom (19%)[34] and approximate to those described in
series of neighboring countries such as Portugal (8.5%)[35]. This discrepancy may be due to
different classification systems and should be interpreted with caution. Mitral regurgitation
and pericardial effusion are more frequent in our cases (6.7%, 7.7%) but mild and transient as
in other series [29,35]. The disparity in the rate of coronary involvement when compared to
Asian series could be related to genetic conditions or to delayed diagnosis of the disease in
European countries due to its lower incidence. In Asian countries they treat children earlier
than in Europe, on the third or fourth day, due to a high index of suspicion, which can also
condition a better prognosis. Compared with the countries in our geographical region, our
percentage of aneurysms is low, and could rely on the presence of pediatricians in primary
care settings and awareness of the disease. Children with coronary aneurysms received IVIG
later than those without (median 10 days vs 7 days) in a study from the UK[34]. In our series,
treatment after 8 days was an independent risk factor despite the timing from the first symp-
tom to diagnosis being less than 10 days in 85% of our children.
The efficacy of IVIG administered in the acute phase of KD is well established to reduce the
prevalence of CAL with higher doses given in a single infusion having the greatest efficacy
[1,36]. In our study treatment with IVIG was given to 97% of the patients, in spite of which, we
have a 15% of patients with resistance to treatment, being in these cases more likely the devel-
opment of aneurysms. This proportion is higher than the 4.9% rate reported by Chen et al[25]
but within the range of 10% to 20% described in the recent American Heart Association
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statement by McCrindle et al in 2017[1]. Steroids were given to 15% of the children in our
study; and only a small proportion initially together with IVIG, reflecting that they are used
mostly in patients who have a poor response to the initial dose of IVIG. Results from the
RAISE (Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for
Kawasaki disease) study showed that addition of prednisolone to the standard regimen of
IVIG improves coronary artery outcomes in patients with severe KD in Japan[37]. Moreover,
a recent Cochrane review concludes that the evidence suggests that treatment with a long
course of steroids should be considered for all children diagnosed with KD [38] although there
are authors calling to take this with caution in unselected non-Japanese populations as two US
trials included in the meta-analysis did not demonstrate significant benefit from primary
adjunctive steroids[39]. Therefore, we need to identify patients with high risk of failure to
treatment and development of aneurysms in order to achieve an earlier and effective treatment
as the validated scores in Asian population (Egami, Sano and Kobayashi) were not of utility in
our population. In our series, the development of aneurysms was independently associated
with a smaller height of the patients (probably indirectly with age), with anemia < 10.2 gr/dL,
with leukocytosis greater than 16,000 cell/mm3 and with a treatment delay of more than 8
days. Therefore, when these factors are present, adding steroids to the initial treatment should
be considered. Age is considered a risk factor (< 12 months of age), and our results confirmed
this, constituting the group of patients that develop aneurysms in a higher proportion. Indeed,
we consider that in children younger than 1 year of age, we should be very cautious and con-
sider beginning treatment with steroids together with IVIG, as many authors are recommend-
ing. For the same reason, some authors recommend performing an echocardiogram on infants
with fever without a source for 7 days or longer with elevated inflammatory markers[1,25]
Our study has several limitations. One of them is that we could not calculate an overall inci-
dence of KD as our network did not achieve total national coverage. The retrospective charac-
ter of our study is also a main limitation, because of missing data in some parameters. Also,
further tests looking for distal lesions in the coronary arteries were made in very few patients
so there is a potential underestimation of persistent CAL. Nevertheless, we think that the num-
ber of patients collected allow us to draw some conclusions in terms of risk factors, that could
be validated in a prospective study already ongoing in the KAWA-RACE group.
More studies are necessary in our population and it would be of interest to validate a score
for non-Japanese children to be able to predict the risk of aneurysm development and treat-
ment failure that would allow for selecting patients that would benefit from early steroids or
other immunosuppressive treatments. Meanwhile, we recommend being extremely cautious
with children under 12 months, with anemia and leukocytosis and to consider adding steroids
early in those patients, especially if the treatment is not started before 8 days of fever.
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